AsurDx™ Nipah Virus (NiV) Antibody cELISA Test Kit
The AsurDxTM Nipah Virus (NiV) Antibody Test Kit is designed for the detection of antibodies specific to Nipah Virus Glycoprotein, which can be detected from multiple species
Feature
- Detects NiV antibodies in multiple species’ serum/plasmas;
- Procedures last less than 1.5 hours;
- Provides a simple, rapid, sensitive and specific competitive enzyme-based immunoassay (cELISA) screening method
*Availability/Distribution: Product is designed and developed by BioStone US Texas headquarter and manufactured/assembled by BioStone oversea subsidiaries or partners. Currently, the product is only available outside of the USA. Regulatory requirements vary by oversea countries; the product may not be available in your geographic area.
Specification
Method | Competitive Colorimetric ELISA (cELISA) |
Coated Antigen | Purified Nipah Virus antigens |
Incubation Time | 60 minutes |
Storage | At least 12 months |
Specificity | Nipah Virus antibodies in multiple species’ serum/plasma including pigs, birds, dogs, cats, goats, horses, and sheep |
Order Information
Catalog Number | 10103-02 | 10103-05 |
Plates | 2 plates | 5 plates |
Reactions | 192 | 480 |
Plate Format | 12 X 8-well strips | 12 X 8-well strips |
About Disease
Nipah Virus (NiV) is an enveloped RNA virus from the genus Henipavirus, in the Paramyxoviridea family, which also includes the closely related Hendra virus (HeV). There are two genetically distinct strains of NiV, Malaysia strain (NiV-M) and Bangladesh strain (NiV-B). The NiV-B strain has significantly higher mortality rates. NiV caused a major outbreak in 1998, due to transmission from bats to pigs and humans in Southeast Asia. In response, 1.1 million pigs were culled to prevent transmission. Smaller outbreaks have occurred every year since its emergence. Although pigs are the primary NiV-amplifying species, several other animal species are susceptible to NiV infections, including dogs, cats, goats, horses, and sheep. Pigs with subclinical infections were a major cause of the first NiV outbreak and continues to pose a biosecurity risk due to the lack of treatments or vaccines.